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Abstract
CATERPILLER is a mammalian gene family with signature NBD and LRR domains. Several
members of this family are positive regulators of inflammatory responses. Others, however, exert
negative effects on proinflammatory responses. These data are particularly convincing when shRNA/
siRNA are used. This review focuses on the Monarch-1/PYPAF7 gene with brief discussions of
CLR16.2/NOD3, PYPAF2/PAN1/NALP2, and PYPAF3.
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The CATERPILLER (CLR) gene family
The discovery of the CLR gene family by our group was prompted by our long-term interest
in the master transcriptional regulator of MHC-II, the class II transactivator (CIITA) [1].
Analyses of domain structures of CIITA by us and others have led to the general depiction of
this protein as containing an N-terminal acidic domain that is critical for transcription
activation, a mid-region nucleotide-binding domain (NBD) and a C-terminal leucine rich
region (LRR) [2,3]. Mutations of these three regions are detrimental to the capacity of CIITA
to activate MHC-II genes. By comparing the domain architecture of CIITA to published gene
sequences, it became clear to us that other genes encode proteins with the same structure,
including the then just-discovered NOD1 protein [3]. Most remarkably, a subgroup of plant
disease-resistance genes encodes proteins with a similar nucleotide-binding domain, and LRR
motifs [4]. Thus we noted over five years ago that the NBD motifs and LRR of these plant
proteins are similar to CIITA with respect to both spacing and size, and suggested a divergent
family of genes with a similar domain structure which protects against infectious agents in both
mammals and plants. In a separate paper, the Nunez group, proposed a similar concept based
on their studies of NOD1 and NOD2, as well as other proteins with similar domains [5].
The simultaneous publication of the initial drafts of the human genome by Celera and a public
consortium in early 2001 allowed a rapid acceleration of our own effort to complete the search
of the CLR gene family [6]. Based on bioinformatics data culled from the Celera human
genome scaffold data and the National Center for Biotechnology Information (NCBI), we
described in detail the CLR family, which in humans is comprised of over 20+ family members.
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The genomic organization of all the family members is remarkably similar with large NBD
exons (≃1500 nt) and LRR exons of either ≃76 nt which we referred to as a singlet LRR, or a
doublet of 174 nt. The N-terminal end containing either a CARD or pyrin domain is typically
≃300 nt long. We also noted and compared the relatedness of this family to the NAIP and
IPAF/CARD12, and to its more distant cousin, the APAF-1 gene. From a historic perspective,
it is rather remarkable that the entire family and its close relatives were identified in one felt
swoop, testifying to the impact of the human genome project. Soon thereafter, another group
reported on a nearly-identical gene family and named it the nucleotide-oligomerization domain
(NOD) family after its founding members NOD1 and NOD2 [7,8]. A more recent proposal
suggests the name NACHT-LRR or NLR [9]. Several others reported on the pyrin-containing
subgroup or members of this subgroup, which were given various names including PAN,
PYPAF and NALP [10–12].
A seminal step forward in understanding the biologic function of CLR genes was the
association of certain members of this family with human diseases. Notable examples are the
genetic association of CIAS-1 to three autoinflammatory diseases and of NOD2 to Crohn’s
disease and Blau’s syndrome. Other notable progress includes the findings that NOD1, NOD2
and CIAS-1 are all required for cellular responses to degradation products of bacterial
peptidoglycans. This has led to the concept that these CLR proteins function as “sensors” of
pathogenic products. Finally, another fundamental step forward was the finding that some CLR
proteins are important components of the “inflammasome” [13]. The formation of this multi-
protein complex leads to the activation of caspase-1 and subsequent production of mature
IL-1β. These topics have been discussed in several recent reviews and will not be a focus here
[12,14]. Instead, this review will focus on a pyrin-containing CLR protein which we refer to
as Monarch-1. This protein is found to be a negative regulator of NF-κB activation and
subsequent cytokine and chemokine production. Additional examples of negative regulators
have also emerged from other studies, and will be briefly mentioned.
The Monarch-1/PYAPF7 gene
The 3′ fragment of the gene encoding Monarch-1 was first identified as a gene whose
expression is induced by nitric oxide in the leukemic line, HL60 [15]. The full length sequence
was first cloned and named PYPAF7 [16]. Simultaneously, we also cloned the full length
sequence and named it CLR19.3 or Monarch-1 [17]. The gene is located on human chromosome
19q13.4, among a cluster of nine pyrin-containing CLR genes. The full-length cDNA has a
3189-bp open reading frame (accession number AY116204) encoded by 10 exons. The protein
consists of a predicted N-terminal pyrin domain; a central nucleotide-binding domain, that
belongs to the NACHT subfamily of NTPases containing seven signature motifs; and a leucine
rich region. In addition, we found that there are at least four Monarch-1 splice forms resulting
from differential splicing of the LRR (accession numbers AY116205, AY116206, and
AY116207) (Fig. 1). Preliminary evidence indicates that these splice forms exhibit different
functions, suggesting that varying the length of the LRR may serve to alter the ultimate biologic
activity of the gene product (J. Lich, unpublished observations).
Monarch-1 expression
Monarch-1 is found to be expressed in monocytes and granulocytes with notably high
expression in eosinophils, while a panel of over 70 tissues/cells shows little or no expression
[16,17]. This myeloid restricted pattern of expression provided the initial clue that the protein
may be a regulator of the immune response, inflammation and host response to pathogens. In
examining the mRNA expression, we found that Monarch-1 expression is reduced by greater
than 65–80% after an 1 h treatment with purified E. coli LPS, which activates TLR4, or
peptidoglycan/Pam3Cys, which activates TLR2 [18]. Similarly, live bacteria including M.
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tuberculosis and P. gingivalis all resulted in reduced Monarch-1. This reduced expression is
found in the THP-1 cell line and, more convincingly, in human peripheral blood granulocytes
and monocytes. Confirmation of this reduction in Monarch-1 was also verified at the protein
level. This response in Monarch-1 expression is not limited to TLRs. Indeed, expression is also
down-regulated upon exposure of PBMC to TNFα or IFNγ [18]. These results, coupled with
the functional studies to be reviewed below, have led to hypothesis that Monarch-1 functions
as a negative regulator of inflammatory responses induced by TLRs and cytokines.
In contrast to the observations that Monarch-1 levels decline rapidly under inflammatory
conditions, another group has shown that nitric oxide increases the expression of Monarch-1
[15]. This has been confirmed by us and others [17]. Thus an interesting proposition is that
nitric oxide may serve as a negative feedback loop to induce Monarch-1 expression, which
then attenuates an ongoing inflammatory response by inhibiting NF-κB activation as well as
proinflammatory cytokine and chemokine expression.
Monarch-1 generally exhibits a cytoplasmic pattern of expression. Bertin and colleagues found
that when expressed together with ASC (Apoptotic Speck containing protein with a CARD),
the two proteins co-localize to punctate cytoplasmic structures. However, attempts to co-
precipitate Monarch-1 and ASC have not been successful ([16] and J. Lich, unpublished
observations). This parallels the interaction between CIAS-1 and ASC, which can be detected
in a yeast two-hybrid system, but not by co-precipitation of overexpressed proteins in
mammalian cells. Interestingly, however, co-precipitation with disease-associated CIAS-1
mutants has been demonstrated, indicating that disease-associated mutation resulted in
enhanced interaction with ASC. The confirmation of the physical interaction of Monarch-1
with ASC awaits studies analyzing endogenous proteins.
Monarch-1 function
Bertin et al. found that while Monarch-1 alone does not have much demonstrated function in
293T cells, simultaneous overexpression of Monarch-1 and ASC in these cells is found to result
in NF-kB and caspase-1 activation. However our findings with siRNA directed at Monarch-1
in the monocytic cell line, THP-1, showed very different findings. In THP-1 cells, silencing
Monarch-1 causes a dramatic enhancement of NF-κB activation upon TLR stimulation,
suggesting that endogenous Monarch-1 functions as a negative regulator of the NF-κB response
in monocytes. Furthermore, the production of the proinflammatory cytokines IL-6 and IL-1β
is elevated in Monarch-1 silenced THP-1 monocytes in response to TLR4 agonists (LPS),
TLR2 agonists (Pam3Cys) or whole bacteria (M. tuberculosis) [18]. This negative regulatory
role was confirmed in reciprocal experiments utilizing THP-1 cells stably expressing elevated
levels of Monarch-1. In these cells, greatly reduced levels of proinflammatory cytokines are
produced in response to TLR stimulation (our unpublished observations). Together with the
siRNA results, these finding demonstrate that Monarch-1 performs a negative regulatory role
in controlling the inflammatory response.
Toward identifying the molecular mechanisms of Monarch-1 activity
Monarch-1 functions as a negative regulator of inflammation by suppressing the production
of proinflammatory cytokines and chemokines [18]. Based on reporter gene assays, Monarch-1
exerts this anti-inflammatory function by inhibiting NF-κB activation. Inhibition of NF-κB is
not unique to Monarch-1. Indeed, this phenotype is shared among several CLR proteins such
as PYPAF2 and CLR16.2 [19,20]. Unfortunately, little is known regarding the molecular
mechanisms by which Monarch-1 or these other CLR proteins exert this anti-inflammatory
activity.
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Monarch-1 suppresses TLR-induced expression of NF-κB responsive cytokines in monocytes.
Therefore, to determine how Monarch-1 suppresses NF-κB, we focused our studies on the role
of Monarch-1 in TLR signaling. In this pathway, TLRs associate with cytoplasmic adaptor
proteins, such as MyD88, that recruit the serine/threonine kinases IRAK1 and IRAK4. IRAK4
phosphorylates IRAK1, which activates the autophosphorylation activity of IRAK1. This leads
to the accumulation of a hyperphosphorylated species of IRAK1 [21]. This critical step is
required for activation of TRAF6 and downstream MAP3 kinases. These MAP3 kinases
activate the IKK complex (composed of IKKα, β, and γ), which promotes the activation of
RelA/p50 NF-κB dimers. This “canonical” pathway proceeds rapidly and leads to the
production of inflammatory cytokines and chemokines including IL-6, TNF-α and IL-8 [22].
Our studies have led to the finding that Monarch-1 intersects the TLR signaling pathway
through its association with IRAK1 [18]. The association with IRAK1 is mediated through the
NBD of Monarch-1 and is induced following TLR stimulation. Importantly, this association
results in a sharp reduction in cellular levels of hyperphosphorylated IRAK1. It is not clear
whether this reduction results from an inability to phosphorylate IRAK1 or is due to a rapid
turnover of hyperphosphorylated IRAK1 in the presence of Monarch-1. Nevertheless, the loss
of hyperphosphorylated IRAK1 would, presumably, hinder the activation of downstream
signaling molecules including NF-κB. This supports our findings from reporter gene assays,
where Monarch-1 expression inhibits IRAK1-mediated NF-κB activation [18]. Furthermore,
it provides a possible explanation for the enhanced level of NF-κB activation following TLR
stimulation of monocytes in which Monarch-1 expression has been silenced.
In addition to suppressing canonical NF-κB activation, our studies have found that Monarch-1
also inhibits “noncanonical” NF-κB activation. This alternative pathway occurs subsequent to
the canonical pathway and is activated downstream of TLRs as well as certain TNF family
receptors [23–25]. Unlike the canonical pathway, which can be activated by many different
upstream kinases, the noncanonical pathway is strictly dependent upon the MAP3 kinase NIK
[26]. Upon activation, NIK recruits IKKα and NF-κB2/p100, which leads to the processing of
p100 to its active form p52. Activation of this noncanonical pathway augments the initial
proinflammatory response by regulating the transcriptional activation of chemokines such as
CXCL12, CXCL13 and CCL5 [27] (Fig. 2).
Analogous to our findings concerning Monarch-1 and IRAK1, Monarch-1 associates with NIK
following activation of the kinase and inhibits NIK-induced NF-κB activation (J. Lich et al.
submitted). This was observed both in reporter gene assays and in THP-1 monocytes where
elevated levels of Monarch-1 inhibited p100 processing. Surprisingly, Monarch-1 mediated
inhibition of NIK stems, at least in part, from the ability of Monarch-1 to induce rapid
proteasome mediated degradation of the kinase. To our knowledge, this is the first report of a
CLR protein that controls inflammatory signaling pathways through a proteasome mediated
process.
Based on these studies, a mechanism is emerging where Monarch-1 functions to negatively
regulate innate immune responses by associating with and suppressing key signaling
molecules. In the case of IRAK1, a significant reduction in hyperphosphorylated IRAK1 is
observed in TLR stimulated monocytes expressing elevated levels of Monarch-1 [18]. As stated
earlier, the mechanism by which Monarch-1 reduces hyperphosphorylated IRAK1 is not clear.
However, the results from our NIK studies have led to the hypothesis that hyperphosphorylated
IRAK1 is a target for Monarch-1-induced proteasome mediated degradation. Indeed, in
HEK293 cells expressing both IRAK1 and Monarch-1, the addition of proteasome inhibitors
rescues hyperphosphorylated IRAK1. This indicates that this species of IRAK1 can form in
the presence of Monarch-1; however, its accumulation is limited by proteasome mediated
degradation (J. Lich, unpublished observations). Current studies are underway to determine if
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Monarch-1 induces proteasome mediated degradation of hyperphosphorylated IRAK1 in TLR
stimulated monocytes.
The degradation of signaling molecules following cellular activation provides a potent
mechanism for controlling inflammatory signaling pathways. Our results support a model
where activation leads to the association of Monarch-1 with the active forms of the signaling
proteins IRAK1 and NIK. This interaction leads to rapid degradation of these proteins, thereby
attenuating the inflammatory signaling. Other CLR proteins have been shown to associate with
signaling proteins and suppress their ability to activate NF-κB. For instance, NOD2 associates
with TAK1 and inhibits the ability of TAK1 to activate NF-κB [28]. Similarly, PYPAF2
associates with ASC and the IKK complex and prevents NF-κB activation downstream of a
number of activators [19]. It remains to be seen if these CLR proteins mediate NF-κB
suppression through proteasome-mediated pathways.
Other negative regulatory CLR proteins
Although this review is primarily focused on Monarch-1, several CLRs exhibit negative
regulatory functions including the CLR16.2/NOD3, PYPAF2/PAN1/NALP2, and PYPAF3.
CLR16.2 is expressed primarily in T cells, and similar to Monarch-1, its expression declines
rapidly following cell stimulation [20]. When present, CLR16.2 inhibits NF-κB, AP-1 and
NFAT transcriptional activation in Jurkat T cells downstream of CD3/CD28 stimulation or
treatment with PMA/ionomycin. This suggests that CLR16.2 functions as a novel suppressor
of T cell activation.
PYPAF2 is expressed more broadly than CLR16.2 or Monarch-1 and mRNA can be detected
in many different cell types and tissues, including non-hematopoietic cells [19,29]. In addition,
distinct from Monarch-1 and CLR16.2, PYPAF2 expression is induced following treatment of
cells with LPS or proinflammatory cytokines. PYPAF2 inhibits NF-κB activation downstream
of many different upstream activators. This was shown directly in reporter gene assays and
indirectly in THP-1 monocytes, where siRNA mediated silencing of PYPAF2 results in
increased expression of ICAM1. It appears that PYPAF2 performs this function through its
association with the IKK complex [19]. In addition to the IKK complex, PYPAF2 also
associates with ASC. However, in this case, PYPAF2 acts as a positive regulator by promoting
ASC-mediated caspase-1 activation and IL-1β release. This may result from the ability of
PYPAF2 to form an inflammasome complex. Indeed, another report subsequently found that
PYPAF2 forms a large protein complex consisting of ASC, pro-caspase-1, and CARDINAL/
CARD8 [13].
Similar to PYAF2, PYPAF3 is broadly expressed and induced by LPS or proinflammatory
cytokines [29]. However, in contrast to PYPAF2, PYPAF3 has no measured effect on NF-κB
activation. Instead, PYPAF3 suppresses ASC-mediated IL-1β release by inhibiting the
processing and activation of pro-caspase-1 and pro-IL-1β. This was confirmed in THP-1
monocytes expressing elevated levels of PYPAF3. How PYPAF3 performs this function has
not been elucidated. However, PYPAF3 associates with pro-caspase-1 and pro-IL-1β in co-
precipitations suggesting that it forms a large protein complex similar to that formed by
PYPAF2. As mentioned above, PYPAF2 also associates with pro-caspase-1, but different from
PYPAF3, functions to promote IL-1b release. Thus, even though PYPAF2 and PYPAF3 form
similar protein complexes, they have different functional outcomes.
Current challenges and future directions
Ectopic expression of CLR proteins in model cell lines provides a convenient and powerful
system to explore the molecular mechanisms influenced by these newly discovered genes.
However there is some concern surrounding such overexpression systems, as genes of this
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family have exhibited both positive and negative functions, depending on the dosage used. For
instance, Bruey et al. found that PYAPF2 enhances ASC-mediated IL-1β release at low doses
[19]. This effect was lost as increasing amounts of PYPAF2 were expressed. Furthermore, in
our laboratory, we have observed that higher levels of CIITA are actually detrimental to MHC
class II expression. Even in gene deletion mice, three different strains of NOD2−/−mice exhibit
different positive and negative responses to pathogenic stimulants [14]. Hence while awaiting
the availability of gene deletion mice, the utilization of shRNA or siRNA in combination with
ectopic expression would be most informative.
While much has been learned concerning how CLR genes function in inflammation and
immunity, there is still much to be explored. For instance, NOD1, NOD2, and CIAS1 respond
to components of peptidoglycan. However, it remains unknown whether or not other CLR
family members, such as Monarch-1, also respond to microbial derived molecules. In addition,
very little is known concerning the molecular mechanisms by which the majority of CLR
proteins function. Several CLR proteins have been shown to form large protein complexes
collectively termed ‘inflammasomes” [30]. These complexes have been implicated in
processing IL-1β and IL-18. PYPAF2 associates with these complexes [13]. However, it is not
known how the formation of these large multi-protein complexes relates to the NF-κB
suppressive activity of PYPAF2. Most importantly, with regards to disease associated CLRs,
only after these molecular mechanisms have been elucidated will we be able to understand
how certain mutations lead to autoinflammatory conditions in humans.
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Figure 1. Monarch-1 isoforms
Four different isoforms encoding Monarch-1 have been identified. These isoforms differ due
to mRNA splicing of exons encoding the LRR domain. Listed above is the common name
followed by an exon diagram for each isoform. In addition, the isoform number (I–IV) and
accession number are shown.
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Figure 2. Monarch-1 suppresses both canonical and noncanonical NF-κB activation
Upon TLR stimulation, the adaptor protein MyD88 is recruited to the receptor complex.
MyD88 then recruits IRAK4 and IRAK1 which results in the accumulation of
hyperphosphorylated IRAK1. This leads to the activation of TRAF6 which triggers NF-κB
activation via MAP3 kinases such as TAK1 and NIK. While the canonical pathway can be
activated by a number of upstream kinases, the noncanonical pathway is strictly dependent
upon NIK. Monarch-1 is capable of blocking both pathways through its interactions with
IRAK1 and NIK. Monarch-1 suppresses canonical NF-κB activation by blocking the
accumulation of hyperphosphorylated IRAK1. The noncanonical pathway is also inhibited as
the association of Monarch-1 with NIK leads to rapid proteasome dependent degradation of
the kinase.
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